Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Insilico Medicine の市場拡大を追跡しています
過去 90 日間に 16 件のシグナル。
Insilico Medicine の海外展開を競合と比較
Insilico Medicine自社バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
 Insilico Medicine自社 | 0 | 0 | — | 0 | 0 |
Machine Learning Engineer
求人を見るAbu Dhabi, Abu Dhabi Emirate, United Arab Emirates · 先月
Business Development Manager - AI Platform Technologies
求人を見るTokyo, Japan · 2か月前
Clinical Project Manager (Oncology) Consultant
求人を見るUnited States · 2か月前
Most frontier models continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training.Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.We’re ready to help you integrate these models dire ...
実施中
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
実施中
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
実施中Insilico Medicineは、イーライリリーのAndrew Adamsが率いる業界初の長寿委員会を設立し、AI駆動の老化研究と生物学的老化プロセスと健康寿命延長を標的とする創薬を監督する。
インシリコ・メディシンが業界初の長寿委員会を設立し、AI駆動の老化研究と創薬に科学的監督を提供。老化と疾患メカニズムに対処する二重目的標的に焦点を当てる。
インシリコ・メディシンは、30番目のAI駆動前臨床候補ISM0387を指名。UAE初の開発候補で、膠芽腫を標的とするMTA協調PRMT5阻害剤を生成AIプラットフォームで12ヶ月で完成。
認証済みメールと直通電話を解放
無料 · カード不要
Insilico Medicine の事業、市場、成長シグナルに関する簡潔な回答。
© 2026 Pubrio. 無断転載を禁じます。
